Cite

HARVARD Citation

    Boddu, P. et al. (2019). Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leukemia & lymphoma. 60 (13), pp. 3172-3180. [Online]. 
  
Back to record